ONON inventory forecast 2025 refers back to the predicted efficiency of Onconova Therapeutics, Inc. (ONON) inventory over the following few years. It will be important for traders to contemplate inventory forecasts as they’ll present priceless insights into the potential development and profitability of an organization.
ONON is a clinical-stage biopharmaceutical firm centered on discovering and growing novel most cancers therapies. The corporate’s lead product candidate, rigosertib, is a small molecule that targets a number of signaling pathways concerned in most cancers development and survival. Rigosertib is presently being evaluated in a number of scientific trials for the therapy of varied varieties of most cancers, together with lung most cancers, breast most cancers, and pancreatic most cancers.
